Medication and Weight Gain: The Conversation Nobody Starts Early Enough
Weight gain is one of the most common reasons people stop psychiatric medication — and one of the least discussed before the first prescription. What the evidence says, and what to ask for.
Ask people who have taken psychiatric medication for more than a year what surprised them most, and weight comes up again and again. Not as a footnote, but as the thing that changed how they felt in their body, how they were looked at, and — for a significant number — whether they kept taking the drug at all. Surveys of people on antipsychotics consistently find weight gain among the top reasons for stopping without telling anyone. That makes it a treatment issue, not a cosmetic one.
This article is not an argument against medication. Antipsychotics and mood stabilisers prevent relapse, hospitalisation and, in the case of lithium, suicide. Stopping abruptly is one of the most dangerous things a person with a serious mental illness can do. The honest position is that these drugs can be both necessary and metabolically costly, and that the cost is far more manageable when it is named at the start rather than three stone later.
Why it happens. Weight change on psychiatric medication is not simply a matter of eating more, although appetite is part of it. Several antipsychotics block histamine H1 and serotonin 5-HT2C receptors, which raises hunger and reduces the signal that a meal has ended. Some also reduce resting energy expenditure and alter insulin sensitivity and lipid handling directly, which is why metabolic markers can shift within weeks — sometimes before any visible weight change. Sedation reduces movement. Illness itself reduces movement. These effects stack.
The risk is not uniform. Olanzapine and clozapine carry the highest average weight gain, with clinically significant gain common in the first months. Quetiapine and risperidone sit in the middle. Aripiprazole, ziprasidone and lurasidone are generally weight-neutral or close to it. Mood stabilisers differ too: valproate and lithium are associated with gain, lamotrigine much less so. Among antidepressants, mirtazapine and paroxetine are the usual culprits; sertraline and fluoxetine are more neutral, with modest gain over years. Individual response varies widely — averages describe populations, not you.
The first three months matter most. Early weight gain is the strongest available predictor of longer-term gain. A commonly used clinical threshold is a rise of more than five per cent of body weight in the first month; when that happens, it is a reason to review, not to wait and see. This is exactly why baseline measurements before the first dose are worth insisting on.
What good monitoring looks like. Weight and waist circumference at baseline and then at weeks four, eight and twelve, and at least annually after that. Blood pressure, fasting glucose or HbA1c, and a lipid panel at baseline, at three months and annually. In Germany this falls to the prescribing psychiatrist and the Hausarzt together, and is a reasonable thing to request explicitly; the Check-up 35 covers part of it from age 35. In the UK, NICE guidance places physical health monitoring for people on antipsychotics with the prescriber for the first year and with the GP thereafter. Audits in both systems repeatedly show it is done less often than the guidelines require — which means asking for it is not being a difficult patient.
What can be done, in rough order of evidence. First, switching. Where the illness is stable and the drug is not the only one that has worked, moving to a lower-risk agent can reverse part of the gain. This is a specialist decision and never a solo one. Second, metformin. Adding metformin alongside antipsychotics has reasonable trial evidence for limiting and modestly reversing weight gain, and it is often underused. Third, structured lifestyle programmes. Combined diet-and-activity interventions designed for people on antipsychotics work better than generic advice, particularly when started early. Fourth, GLP-1 receptor agonists such as semaglutide and liraglutide, where trials in antipsychotic-related weight gain are promising and growing, though access, cost and reimbursement vary by country and indication.
What tends not to work: being told to eat less and move more, without acknowledgement that the drug is changing the hunger signal itself. That framing is common, and it reliably produces shame rather than change.
Sleep, timing and the ordinary stuff still count. Sedating doses taken earlier in the evening can leave less late-night eating and a less flattened next morning. Protein and fibre at breakfast blunt the appetite curve for some people. Resistance training preserves muscle mass, which matters more than the number on the scale for metabolic risk. None of this is a substitute for the four options above, but it is not nothing.
The bigger picture. People with serious mental illness die on average fifteen to twenty years earlier than the general population, and the majority of that gap is cardiovascular and metabolic, not suicide. Treating weight and metabolic health as a serious part of psychiatric care — rather than a side conversation — is one of the clearest places where holistic care and evidence-based medicine point in exactly the same direction.
What to ask at your next appointment: What is this drug's weight and metabolic profile compared with the alternatives? What are my baseline numbers, and when will we recheck them? At what point would we consider switching or adding metformin? Who is responsible for the physical monitoring — you or my GP?
And the one thing not to do: do not stop or reduce the dose on your own. Bring the problem to the prescriber instead. Weight gain is a reason to change the plan, not a reason to abandon treatment.